HORIZON-PFT: Pivotal Fracture Trial
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00049829 |
Recruitment Status :
Completed
First Posted : November 15, 2002
Last Update Posted : November 2, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Osteoporosis | Drug: Zoledronic Acid | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 7700 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | HORIZON-PFT: Pivotal Fracture Trial |
Study Start Date : | January 2002 |
Actual Primary Completion Date : | June 2006 |
- Incidence of hip fxs
- Incidence of new vertebral fxs
- Percent change in hip BMD
- New and/or worsening vertebral fxs
- All clinical fxs
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 65 Years to 89 Years (Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Female, 65-89 years old
- No history of severe liver, kidney or eye disease
Exclusion Criteria:
- Current bisphosphonate users such as Aredia® (pamidronate), Didronel® (etidronate), Fosamax® (alendronate), Actonel® (risedronate), Skelid® (tiludronate)
- Using hip protectors
Other protocol-defined inclusion/exclusion criteria may apply.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00049829
Responsible Party: | Novartis Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00049829 |
Other Study ID Numbers: |
CZOL446H2301 |
First Posted: | November 15, 2002 Key Record Dates |
Last Update Posted: | November 2, 2011 |
Last Verified: | November 2011 |
Bisphosphonate,BMD,Height loss, Hip protectors,HRT, Osteoporosis |
Osteoporosis Bone Diseases, Metabolic Bone Diseases Musculoskeletal Diseases |
Metabolic Diseases Zoledronic Acid Bone Density Conservation Agents Physiological Effects of Drugs |